

Appendix 4E

Preliminary Final Report

1. Company details

Name of entity

Pro Medicus Limited

ABN or equivalent
company reference

25 006 194 752

Financial year ended
(‘current period’)

30 June 2013

Financial year ended
(‘previous period’)

30 June 2012

2. Results for announcement to the market

ASX Listing Rules Ref		2013 A\$'000
2.1	<p>Revenue from continuing operations</p> <p>% change up/(down) of revenue from ordinary activities from the previous corresponding period.</p>	<p>11,374</p> <p>Down 0.04%</p>
2.2	<p>Profit after tax attributable to members</p> <p>% change up/(down) of Profit/(Loss) from ordinary activities after tax attributable to members from the previous corresponding period.</p>	<p>5,131</p> <p>Up 186.5%</p>
2.3	<p>Net Profit for the period attributable to members</p> <p>% change up/(down) of Net Profit/(Loss) for the period attributable to members from the previous corresponding period.</p>	<p>5,131</p> <p>Up 186.5%</p>

2.4	Dividends (distributions)	Amount per security	Fully Franked amount per security
	Franked dividend amount per security		
	Final Dividend	1.0 cents	1.0 cents
	Interim dividend	1.0 cents	1.0 cents
2.5	Record date for Final dividends	13 September 2013	
	Payment date for Final dividends	4 October 2013	

<p>2.6</p>	<p>Australia</p> <p>The Group employs 28 people in Australia who undertake research and development of Pro Medicus products (RIS) as well as sales and service/support functions.</p> <p>The Group's Australian revenue was marginally above last year's result despite an increasingly competitive local market with overall profit being affected by increased costs associated with the ongoing commercialisation and rollout of the Company's new Coral RIS technology platform.</p> <p>Promedicus.net, the company's e-health offering, continued to hold its strong market position despite increasing competition.</p> <p>North America</p> <p>The Group employs 8 people in North America to fulfil the sales marketing and professional services roles. Revenue from North America increased by 26.9% compared to the previous year. This was largely attributable to an increase in transaction based revenue from sales of Visage technology as more contracts come on stream as well as an increase in Original Equipment Manufacturer (OEM) sales.</p> <p>Europe</p> <p>Pro Medicus established a presence in Europe with the acquisition of Visage Imaging GmbH in late January 2009. The group has 38 employees in its Berlin office who undertake research and development of Visage Imaging products worldwide as well as sales, marketing and service/support functions for the group's European operations. Revenue from our European operations decreased by 22.6% compared to the previous year due to deteriorating European market conditions.</p> <p>Financials</p> <p>Full year revenue of the Group from continuing operations, decreased marginally from \$11.38m to \$11.37m, a decrease of 0.4%.</p> <p>The result from the underlying operations for the year was a loss of \$0.65m. The underlying loss is made up of reported profit after-tax of \$5.13m, less the after-tax profit of \$8.61m of Amira and after-tax net currency gain of \$0.39m, and adding back the after-tax impairment expense of \$3.22m. This result was impacted by additional costs, mainly associated with the ongoing commercialisation and roll out of Coral RIS to the market</p> <p>Profit after tax for the period was \$5.13m an increase of 186.5% from the previous year.</p> <p>The key driver of the profit increase was the sale of Amira business in July 2012 which generated a one-off after-tax profit of \$8.61m. This was partially offset by a decrease in the carrying value of some of the company's intangible assets which resulted in an after-tax impairment loss of \$3.22m.</p> <p>Shareholder Returns</p> <p>The directors are confident that the holdings of reserve cash is sufficient to underpin the development and expansion needs of the company as the business looks to increase its penetration of existing markets.</p>
<p>3.</p>	<p>Statement of Comprehensive Income</p> <p>Please refer to the Statement of Comprehensive Income in the attached Financial Statements.</p>
<p>4.</p>	<p>Statement of Financial Position</p> <p>Please refer to the Statement of Financial Position in the attached Financial Statements.</p>
<p>5.</p>	<p>Statement of cash flows</p> <p>Please refer to the Statement of cash flows in the attached Financial Statements.</p>

6.	<p>Details of Dividends</p> <table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2013</th> <th style="text-align: right; width: 15%;">2012</th> </tr> <tr> <th></th> <th style="text-align: right;">\$'000</th> <th style="text-align: right;">\$'000</th> </tr> </thead> <tbody> <tr> <td colspan="3">Final Dividend</td> </tr> <tr> <td>A Final Dividend of 1.0 cents (2012: 1.0 cents) per share fully franked will be paid on 4th October 2013.</td> <td style="text-align: right;">1,002</td> <td style="text-align: right;">1,002</td> </tr> <tr> <td colspan="3">Current Year Interim</td> </tr> <tr> <td>An interim dividend of 1.0 cents (2012: 0.50 cents) per share fully franked was paid on 22 March 2013.</td> <td style="text-align: right;">1,002</td> <td style="text-align: right;">501</td> </tr> <tr> <td colspan="3">No foreign sourced dividend or distribution is included in either the interim or final dividends.</td> </tr> </tbody> </table>		2013	2012		\$'000	\$'000	Final Dividend			A Final Dividend of 1.0 cents (2012: 1.0 cents) per share fully franked will be paid on 4 th October 2013.	1,002	1,002	Current Year Interim			An interim dividend of 1.0 cents (2012: 0.50 cents) per share fully franked was paid on 22 March 2013.	1,002	501	No foreign sourced dividend or distribution is included in either the interim or final dividends.		
	2013	2012																				
	\$'000	\$'000																				
Final Dividend																						
A Final Dividend of 1.0 cents (2012: 1.0 cents) per share fully franked will be paid on 4 th October 2013.	1,002	1,002																				
Current Year Interim																						
An interim dividend of 1.0 cents (2012: 0.50 cents) per share fully franked was paid on 22 March 2013.	1,002	501																				
No foreign sourced dividend or distribution is included in either the interim or final dividends.																						
7.	<p>Dividend or Distribution reinvestment plans</p> <p>There are no dividend or distribution reinvestment plans in operation.</p>																					
8.	<p>Statement of Retained Earnings</p> <p>Please refer to Statement of Changes in Equity in the attached Financial Statements.</p>																					
9.	<table border="0" style="width: 100%;"> <thead> <tr> <th style="width: 70%;"></th> <th style="text-align: right; width: 15%;">2013</th> <th style="text-align: right; width: 15%;">2012</th> </tr> </thead> <tbody> <tr> <td>Net Tangible Assets per security</td> <td></td> <td></td> </tr> <tr> <td>Net Tangible Assets per security</td> <td style="text-align: right;">\$0.15</td> <td style="text-align: right;">\$0.05</td> </tr> </tbody> </table>		2013	2012	Net Tangible Assets per security			Net Tangible Assets per security	\$0.15	\$0.05												
	2013	2012																				
Net Tangible Assets per security																						
Net Tangible Assets per security	\$0.15	\$0.05																				
10.	<p>Details of entities over which control has been gained or lost during the period</p> <p>There are no entities over which control has been gained or lost during the period</p>																					
11.	<p>Associates and joint venture entities</p> <p>There are no associates or joint venture entities</p>																					
12.	<p>Other significant information needed by an investor to make an informed assessment of the entity's financial performance and financial position.</p> <p>Please refer to section 2.6</p>																					
13.	<p>Foreign Entity accounting standards</p> <p>Australian Accounting Standards & International Financial Reporting Standards</p>																					

14.	<p>Commentary on results for the period. The earnings per security and the nature of any dilution aspects. Please refer to Note 9 of the attached Financial Statements.</p> <p>Returns to shareholders including distributions and buy backs. Please refer to Note 10 of the attached Financial Statements.</p> <p>Significant features of operating performance. Please refer to section 2.6.</p> <p>The results of segments that are significant to an understanding of the business. Please refer to Note 5 of the attached Financial Statements.</p> <p>Discussion of trends in performance. Please refer to section 2.6.</p>
15.	<p>Audit Statement</p> <p>This report is based on accounts to which one of the following applies. (Tick one)</p> <p><input checked="" type="checkbox"/> The +accounts have been audited. <input type="checkbox"/> The +accounts have been subject to review.</p> <p><input type="checkbox"/> The +accounts are in the process of being audited. <input type="checkbox"/> The +accounts have <i>not</i> yet been audited or reviewed.</p>

Sign here:

Date: 23 August 2013



Print name: Sam Hupert
Chief Executive Officer